Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India
  • USA - English

Illumina, Inc.

News provided by

Illumina, Inc.

04 Aug, 2021, 07:00 IST

Share this article

Share toX

Share this article

Share toX

SAN DIEGO, Aug. 4, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai, to help expand SARS-CoV-2 sequencing capabilities in the region and support the broader genomic surveillance effort across India. Kasturba Hospital was the first hospital in Mumbai to begin sequencing SARS-CoV-2 this year and will examine how variants of the virus are being spread across India.

"Illumina believes in democratization of access to sequencing and we are committed to helping the regions of the world that carry most of the infectious disease burden to build genomics capabilities," said Francis deSouza, Chief Executive Officer of Illumina. "This donation will help to make NGS technology and expertise accessible in Mumbai, supporting the region and contributing to genomic surveillance in India more broadly."

"We are grateful for Illumina's support in the pandemic fight," said Dr. Jayanthi Shastri, Laboratory Director from the Molecular Diagnostic Reference Laboratory at Kasturba Hospital.

The donation includes two of Illumina's newest next-generation sequencing (NGS) platforms, the NextSeq™ 2000, reagents, a rapid bioinformatics analysis platform (DRAGEN) and four years of service support for the sequencing installations. It is part of Illumina's broader philanthropic program to provide access to NGS technology throughout the world to drive a global response that will be effective in supporting SARS-CoV-2 control efforts.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Source: Illumina, Inc.

Logo - https://mma.prnewswire.com/media/1586483/hires_illumina_logo_rgb_Logo.jpg

Related Links

www.illumina.com

Modal title

Also from this source

Illumina द्वारा SomaLogic का अधिग्रहण किया जाएगा, जिससे उसके प्रोटिओमिक्स बिज़नेस में तेजी आएगी और कंपनी की मल्टीओमिक्स रणनीति आगे बढ़ेगी

Illumina द्वारा SomaLogic का अधिग्रहण किया जाएगा, जिससे उसके प्रोटिओमिक्स बिज़नेस में तेजी आएगी और कंपनी की मल्टीओमिक्स रणनीति आगे बढ़ेगी

Illumina, Inc. (NASDAQ: ILMN) ने घोषणा की है कि उसने Standard BioTools (NASDAQ: LAB) जिसके तहत Illumina द्वारा डेटा-संचालित प्रोटिओमिक्स टेक्नोलॉजी...

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Infection Control

Infection Control

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.